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New technologies and metabolic control  
in type 1 diabetes mellitus
ABSTRACT
The introduction of more rigorous criteria of metabolic 
control, rapid- and long-acting insulin analogues and the 
advances in diabetes technology (improved insulin deliv-
ery systems and blood glucose monitoring) have not been 
translated into better glycaemic control in patients with 
type 1 diabetes, which is quite similar to that observed 
20–30 years ago in the Diabetes Control and Complica-
tions Trial (DCCT). Continuous subcutaneous insulin 
infusion (CSII) provided by personal insulin pumps may 
improve glycaemic control; however, observed results are 
not so good as it has been expected and are only slightly 
better or similar to these obtained with multiple daily 
insulin injections (MDII). Real-time continuous glucose 
monitoring (CGM) seems to be very useful to achieve 
target glycaemic control and to avoid hypoglycaemia in 
both CSII and MDII patients. While using CGM, levels of 
HbA1c are lower, time spent in hypoglycaemia is shorter 
and frequency of hypoglycaemia episodes is reduced. To 
receive optimum benefit, excellent compliance and fre-
quent readings of measurements are required. The most 
common real-time sensors used in Poland are: Medtronic 
Enlite, Dexcom G4 Platinum and Abbott FreeStyle Libre. 
Unfortunately, for majority of patients with type 1 diabe-
tes CGM devices have no reimbursement. (Clin Diabetol 
2017; 6, 3: 111–114)
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Metabolic control in type 1 diabetes  
remains unsatisfactory
According to current guidelines, recommended 
values of HbA1c in young patients with type 1 diabetes 
are ≤ 6.5% or at least ≤ 7%, while avoiding hypoglycae-
mia [1, 2]. Despite more rigorous criteria of metabolic 
control, the introduction of rapid- and long-acting in-
sulin analogues and significant technological advances 
in insulin administration and glycaemic monitoring, 
metabolic control in type 1 diabetes patients remains 
unsatisfactory. In the US study involving more than 
16,000 patients with type 1 diabetes treated in spe-
cialist centres, mean HbA1c value was 8.4%, although 
more than 60% of these patients were treated with 
personal insulin pumps [3]. Mean HbA1c values were: 
in children 8.2% (younger children) to 8.5% (older chil-
dren), in teenagers (13 to 17 years) — 9.0%, in young 
adults (18 to 25 years) — 8.7% and in patients older 
than 25 years — 7.6%. A maximum value of 9.2% was 
reported in 19-year-olds. Overall, target HbA1c values 
were only observed in 23% of patients — in 22% of 
children, 17% of teenagers, 14% of young adults and 
30% of those older than 25 years of age. In almost all 
age groups, diabetes control was worse than a few 
years ago. Unsatisfactory metabolic control was also 
observed in more than 27,000 young patients with 
type 1 diabetes assessed in Germany and Austria [4].
The results of these studies indicate that the 
metabolic control of type 1 diabetes has not changed 
significantly since the Diabetes Control and Complica-
tions Trial (DCCT), in the 1990s. It is worth recalling that 
in the DCCT mean HbA1c value in the intensive group 
was 7.2%, while in the conventionally treated group 
— 9.1% [5]. In the Epidemiology of Diabetes Interven-
tions and Complications (EDIC) study, a continuation 
of the DCCT, despite intensification of treatment in all 
study participants, HbA1c values were almost identical 
in both groups (approximately 8.0%) [6].
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Effects of treatment with personal  
insulin pumps
It is believed that the use of personal insulin pumps 
(PIPs) is superior to multiple daily insulin injection (MDII) 
regimen, but the effects are not as good as one would 
expect. In a follow-up study conducted in the USA, 
mean HbA1c values in PIP and MDII groups were as 
follows: in children under 13 years — 8.3% and 8.7%, 
respectively; in 13–25-year-olds — 8.7% and 9.3%; and 
in patients older than 25 years — 7.7% and 7.8%. The 
analysis of randomized clinical trials in type 1 diabetes 
patients performed by Golden et al. showed that PIP 
and MDII were similarly effective in reducing HbA1c and 
lowering the risk of severe hypoglycaemia in children 
and adolescents, while in adults there was a difference 
in HbA1c values between patients treated with PIP and 
MDII amounting to 0.3%, in favour of PIP [8]. It should 
be stressed that the difference observed in adults in this 
meta-analysis was caused by the spectacular results 
of one study [9]. After excluding that study from the 
meta-analysis, PIP and MDII showed similar efficacy also 
in adults [8]. The very low advantage of PIP over MDII 
has also been confirmed by Misso et al. who analysed 
the results of 23 randomized clinical trials involving 
almost one thousand patients and confirmed a small 
difference in HbA1c of approximately 0.3% in favour 
of pump therapy [10]. In this analysis, the incidence of 
mild hypoglycaemia was similar for PIP and MDII, while 
severe hypoglycaemia was observed less frequently in 
those using PIP. Personal insulin pump therapy was 
also associated with better quality of life of patients.
Recent clinical trials confirm previous observations 
[11, 12]. The results of a randomized RESPOSE trial in-
dicate that the introduction of PIP therapy in patients 
with type 1 diabetes is associated with effects similar to 
those of intensive insulin therapy with MDII [11]. After 
providing all the patients with the same intensive insu-
lin therapy training, including insulin dose adjustment 
for food intake, current glycaemia and exercise, there 
were no significant differences in HbA1c values between 
PIP and MDII groups. The proportion of patients who 
achieved HbA1c ≤ 7.5% was similar in both groups and 
surprisingly low — after 6 months it was about 21%, 
after 1 year — 23%, and after 2 years — 23 to 25%. 
Both groups showed a significant and very similar re-
duction in the frequency of severe hypoglycaemia. The 
patients using PIP reported better quality of life and 
greater satisfaction with treatment. Another clinical 
trial — the COMISAIR Study — also showed slight dif-
ferences in HbA1c between patients with type 1 diabetes 
treated with PIP vs. MDII, with glucose self-monitoring 
conducted in both groups [12]. HbA1c values in patients 
treated with PIP were lower in the consecutive one-year 
periods by 0.1–0.2% compared to those treated with 
the MDII, although this parameter has improved in 
both groups. The incidence of severe hypoglycaemia 
was similar in both groups.
Effects of continuous glucose monitoring
Impact on glycaemia
It seems that the method that allows for a definite 
improvement in HbA1c values in both PIP- and MDII-
-treated patients is continuous glucose monitoring 
(CGM). A large American observational study indicates 
that the use of CGM in patients with type 1 diabetes 
treated with PIP results in a reduction in HbA1c level by 
0.6% in children, 0.6% in adolescents and young adults 
and about 0.4% in patients older than 25 years. The use 
of CGM also has a significant effect on HbA1c values in 
patients on MDII therapy. In children HbA1c levels were 
reduced by 0.8%, in adolescents and young adults by 
1.1% and in patients over 25 years of age by 0.5% [7]. 
In all age groups, the patients using CGM had similar 
HbA1c values regardless of whether they were on PIP or 
MDII. Data from a systematic review and meta-analysis 
of 14 studies involving more than 1.2 thousand patients 
with type 1 diabetes showed slightly lower effective-
ness of CGM in improving glycaemic control [13]. The 
reduction of HbA1c in subjects using CGM compared to 
standard self-monitoring group was only about 0.25% 
in children and adolescents and about 0.3% in adults. 
At the same time, a higher proportion of patients 
achieving HbA1c targets and fewer hypoglycaemic 
episodes were observed in the CGM group [13].
However, the latest publications indicate that CGM 
is much more effective. A Czech study showed that the 
use of the CGM system significantly reduces HbA1c 
and lowers the risk of hypoglycaemia in both PIP- and 
MDII-treated patients [12]. Over the 12 months of 
observation, HbA1c values in the PIP-treated patients 
using CGM decreased by about 1.1%, while in the 
MDII-treated patients using CGM, the HbA1c reduction 
was approximately 1.3%. In both groups, the difference 
in HbA1c between CGM and standard self-monitoring 
(with both PIP and MDII) was approximately 0.8% at 
the end of the study. The test results have been the 
basis for the statement that the MDII method combined 
with CGM may be an equivalent alternative to the 
PIP therapy with CGM. The data from the GOLD and 
DIAMOND trials confirm high effectiveness of CGM in 
patients treated with MDII [14, 15]. In CGM patients, 
HbA1c values were lower by 0.4 to 0.6% compared to 
those using standard self-monitoring.
The above-mentioned studies (GOLD and DIA-
MOND) as well as the IMPACT study have shown that 
good cooperation with patients and patients’ compli-
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ance of at least 80% is a prerequisite for improvement 
in metabolic control [14–16].
According to other authors, combining PIP with 
CGM is particularly beneficial, because the HbA1c values 
in patients using this type of therapy may be 0.6% lower 
than in those using CGM with MDII [17].
Hypoglycaemia risk reduction
An increased risk of hypoglycaemia is an important 
factor limiting the effectiveness of treatment in type 
1 diabetes. Continuous glucose monitoring systems 
contribute to better glycaemic control by more effi-
ciently adjusting insulin doses to glycaemic trends and 
reducing the incidence of hypoglycaemia, or at least 
not affecting its frequency [8, 13]. CGM also allows 
for shortening of the total time of hypoglycaemia. In 
a study conducted in children and adults with type 1 
diabetes and HbA1c < 7.5%, total daily time of hypo-
glycaemia in subjects with standard self-monitoring 
was 0.97 ± 1.55 hours, while in subjects using CGM it 
was 0.48 ± 0.57 hours. Continuous glucose monitoring 
was associated with reduced hypoglycaemia time and 
a decrease in HbA1c levels [18]. A similar reduction in 
time spent in hypoglycaemia (from 11.4% to 6.8%) was 
found in the IN CONTROL study, which also showed 
a 3-fold reduction in the incidence of severe hypogly-
caemia [19]. In a Juvenile Diabetes Research Foundation 
(JDRF) study performed in patients with well-controlled 
metabolic syndrome (HbA1c < 7%), after 6 months 
of CGM, time spent with glycaemia < 70 mg/dL was 
reduced by more than 40%, although no difference 
was observed in the frequency of hypoglycaemia and 
severe hypoglycaemia [20].
Continuous glucose monitoring systems
Devices for continuous glucose monitoring have 
been used in clinical practice for several years. Practical 
application in self-monitoring is limited to real-time 
glucose concentration recorders. The order of ap-
pearance of these devices is as follows: GlucoWatch 
G2, Medtronic RT-Guardian, Abbott FreeStyle Naviga-
tor CGM, Medtronic RT-CGM, Dexcom SEVEN Plus, 
Medtronic Enlite, Dexcom G4 Platinum, and Abbott 
FreeStyle Libre [21]. Almost all, except for the latter, 
require 2 to 4 calibrations per day by measuring capil-
lary blood glucose with classic glucose meter. Alarms 
can be set for certain glycaemic values. The exception 
is the latest FreeStyle LibreTM device, which uses a new 
“flash” technology and is calibrated by the manufac-
turer. Hence this device does not need to be calibrated 
by the patient using capillary blood glucose. The device 
shows current glucose concentrations and trends, but 
unlike the others, it has no alarm function. In Poland, 
the most common systems for continuous monitoring 
of blood glucose are: Medtronic Enlite, Dexcom G4 
Platinum and Abbott FreeStyle Libre. These systems con-
sist of a sensor, a transmitter and a monitor device. The 
CGM technology is based on a semi-invasive method 
of detecting of the current generated in the glucose 
oxidase-catalysed reaction by the sensor placed in the 
subcutaneous tissue. This enzyme is responsible for 
the oxidation of b-D-glucopyranose of the intracellular 
fluid to gluconic acid. Values recorded by the sensor are 
converted into glucose concentration in the recording 
device. The sensor can be placed precisely in subcuta-
neous tissue with a special inserting device (a serter) 
within the areas of the body where the thickness of 
the subcutaneous fat is sufficient. The location of the 
sensor is dependent on the clothes worn, convenience, 
individual preference or experience. It is recommended 
to avoid sites of recent insulin administration. Manufac-
turers of CGM recommend the abdominal area, upper 
buttocks, and arms as sensor locations; however, every 
sensor manufacturer has its own recommendations. 
The transmitter is connected to the sensor. Often, the 
sensor and the transmitter are an inseparable whole. 
The role of the transmitter is to transmit data to 
a monitoring device that can be an independent tool 
and can also be integrated into an insulin pump. 
Increasingly frequent use of continuous glucose 
monitoring systems increases the involvement of 
patients in controlling their own disease, which con-
tributes to HbA1c reduction without increasing the risk 
of hypoglycaemia. Unfortunately, continuous glucose 
monitoring systems are not reimbursed for patients 
over 18 years of age by the National Health Fund.
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